MedicineNews.net - Medical Updates


Janssen has announced that use of the investigational agent Canagliflozin substantially has lowered blood glucose levels when used as add-on therapy in patients on insulin therapy for type 2 diabetes and who are considered to be at greater risk for cardiovascular disease.
These results were presented at the 48th European Association for the Study of Diabetes ( EASD ) Annual Meeting.

CANVAS ( CANagliflozin cardioVascular Assessment Study ) is a prospective, double blind, placebo-controlled trial designed to evaluate the efficacy, tolerability and cardiovascular safety of Canagliflozin in 4,330 adult patients with type 2 diabetes considered at elevated risk for cardiovascular disease.